Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Petros Christopoulos

Showing results (21-30 of 171) with videos related to

Pageof 18
Sort By:
Cureus|November 26, 2021
The Early Changes in Emergency General Surgery Following Implementation of UK COVID-19 Policy: A Retrospective Cohort StudyJoseph Hanger, Alexander Bush, Adam Lunt, et al.
Clinical and Translational Science|November 22, 2020
Pharmacoenhancement of Low Crizotinib Plasma Concentrations in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer using the CYP3A Inhibitor CobicistatNicolas Hohmann, Farastuk Bozorgmehr, Petros Christopoulos, et al.
Translational Lung Cancer Research|March 4, 2022
High efficacy of alectinib in a patient with advanced lung adenocarcinoma with 2 rare <i>ALK</i> fusion sites: a case reportYan Li, Peng Duan, Yan Guan, et al.
Translational Lung Cancer Research|March 4, 2022
<i>TP53</i> co-mutations as an independent prognostic factor in 2nd and further line therapy-<i>EGFR</i> mutated non-small cell lung cancer IV patients treated with osimertinibJulia Roeper, Petros Christopoulos, Markus Falk, et al.
Cureus|March 23, 2026
Impact of Routine Intraoperative Lithotripsy on Surgical Strategy and Outcomes in Laparoscopic Bile Duct Exploration: A Single-Centre Cohort StudyIslam Elsamalouty, Aayush Gupta, Michael Whitmore, et al.
Translational Cancer Research|April 14, 2025
The identification and prediction of lung adenocarcinoma prognosis using a novel gene signature associated with DNA replicationXiujuan Wu, Qiang Xu, Paerhati Aiyiti, et al.
European Journal of Cancer (Oxford, England : 1990)|June 23, 2022
Trends in age- and sex-specific lung cancer mortality in Europe and Northern America: Analysis of vital registration data from the WHO Mortality Database between 2000 and 2017Philip Baum, Hauke Winter, Martin E Eichhorn, et al.
Translational Lung Cancer Research|April 14, 2023
Transformation of <i>ALK</i>-positive NSCLC to SCLC after alectinib resistance and response to combined atezolizumab: a case reportGuohao Xia, Jiayuan Huang, Jie Ni, et al.
British Journal of Cancer|April 29, 2023
Integrated circulating tumour DNA and cytokine analysis for therapy monitoring of ALK-rearranged lung adenocarcinomaArlou Kristina Angeles, Florian Janke, Ann-Kathrin Daum, et al.
Frontiers in Oncology|May 21, 2024
Activity of afatinib in patients with NSCLC harboring novel uncommon <i>EGFR</i> mutations with or without co-mutations: a case reportPetros Christopoulos, Franziska Herster, Petra Hoffknecht, et al.
Pageof 18

Showing results (21-30 of 171) with videos related to

Sort By:
Pageof 18
Cureus|November 26, 2021
The Early Changes in Emergency General Surgery Following Implementation of UK COVID-19 Policy: A Retrospective Cohort StudyJoseph Hanger, Alexander Bush, Adam Lunt, et al.
Clinical and Translational Science|November 22, 2020
Pharmacoenhancement of Low Crizotinib Plasma Concentrations in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer using the CYP3A Inhibitor CobicistatNicolas Hohmann, Farastuk Bozorgmehr, Petros Christopoulos, et al.
Translational Lung Cancer Research|March 4, 2022
High efficacy of alectinib in a patient with advanced lung adenocarcinoma with 2 rare <i>ALK</i> fusion sites: a case reportYan Li, Peng Duan, Yan Guan, et al.
Translational Lung Cancer Research|March 4, 2022
<i>TP53</i> co-mutations as an independent prognostic factor in 2nd and further line therapy-<i>EGFR</i> mutated non-small cell lung cancer IV patients treated with osimertinibJulia Roeper, Petros Christopoulos, Markus Falk, et al.
Cureus|March 23, 2026
Impact of Routine Intraoperative Lithotripsy on Surgical Strategy and Outcomes in Laparoscopic Bile Duct Exploration: A Single-Centre Cohort StudyIslam Elsamalouty, Aayush Gupta, Michael Whitmore, et al.
Translational Cancer Research|April 14, 2025
The identification and prediction of lung adenocarcinoma prognosis using a novel gene signature associated with DNA replicationXiujuan Wu, Qiang Xu, Paerhati Aiyiti, et al.
European Journal of Cancer (Oxford, England : 1990)|June 23, 2022
Trends in age- and sex-specific lung cancer mortality in Europe and Northern America: Analysis of vital registration data from the WHO Mortality Database between 2000 and 2017Philip Baum, Hauke Winter, Martin E Eichhorn, et al.
Translational Lung Cancer Research|April 14, 2023
Transformation of <i>ALK</i>-positive NSCLC to SCLC after alectinib resistance and response to combined atezolizumab: a case reportGuohao Xia, Jiayuan Huang, Jie Ni, et al.
British Journal of Cancer|April 29, 2023
Integrated circulating tumour DNA and cytokine analysis for therapy monitoring of ALK-rearranged lung adenocarcinomaArlou Kristina Angeles, Florian Janke, Ann-Kathrin Daum, et al.
Frontiers in Oncology|May 21, 2024
Activity of afatinib in patients with NSCLC harboring novel uncommon <i>EGFR</i> mutations with or without co-mutations: a case reportPetros Christopoulos, Franziska Herster, Petra Hoffknecht, et al.
Pageof 18